Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Gap junction protein beta 5 is a member of the connexin family, encoded by the GJB5 gene, and also known as connexin-31.1 (Cx31.1)[3][1]. It forms transmembrane channels (gap junctions) which allow direct transfer of small molecules, ions, and signaling mediators between adjacent cells. These gap junctions are crucial for cell-to-cell electrical and metabolic communication, especially in the epidermis and various epithelial tissues[1][3][2][7]. Mutations in GJB5 can result in inherited skin disorders and have been linked to certain cancers, such as non-small cell lung cancer. The channel complexes formed by this protein are essential for tissue homeostasis, developmental processes, and environmental sensing[1][3]. While direct therapeutic targeting has not been established, its central role in disease highlights potential for drug development or biomarker use.
Channel modulation (for hypothetical or future drugs, regulation of gap junction communication or blocking the channel)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Gap junction protein beta 5 (GJB5 or Cx31.1).